Researchers from the University of Illinois, Chicago report that doxorubicin, a long-established most cancers drug, can block the herpes simplex virus type 1 (HSV-1) in laboratory fashions and in mice. Their findings recommend we would see a brand new remedy choice alongside present antivirals, like acyclovir, on the cabinets, however not simply but. This drug has a couple of hurdles to leap earlier than it’s prepared for scientific use in opposition to the herpes virus.
Most folks carry the Herpes Simplex virus with out realizing it. For the bulk, it stays quiet, often surfacing as a chilly sore or staying hidden totally. For most cancers sufferers, transplant recipients and others whose immune techniques are compromised, nevertheless, the identical virus may cause sight-threatening eye infections, mind irritation and in extreme instances, loss of life.
Study chief Deepak Shukla, a virologist at UIC’s College of Medicine defined in a press launch.
‘This opens up an unexpected, potentially fast-moving path toward treating drug-resistant herpes infections…HSV-1 infections have serious, sometimes life-threatening consequences, and this drug may help save lives.’
A brand new hope for Herpes?
For forty years, docs have had mainly one device to handle it: a household of antiviral medication led by acyclovir. Now a crew on the University of Illinois, Chicago has discovered {that a} second device, one already sitting in hospital pharmacies, would possibly work too.
The drug is doxorubicin (AKA Adriamycin), a chemotherapy treatment used to deal with breast most cancers, lymphoma, and different cancers for the reason that Sixties. In a research revealed this January within the journal Drug Resistance Updates, the UIC crew confirmed that doxorubicin can block Herpes Simplex Virus sort 1 (HSV-1) from infecting and replicating in human cells, pig corneal tissue, and mice; together with uncommon strains of the virus that now not reply to acyclovir.
Why a most cancers drug? The quick reply is that it got here up in a pc search. In 2024, Shukla’s lab constructed a digital screening device known as HerpDock, which combs via the libraries of recognized chemical compounds and flags those that may be efficient in opposition to herpes.
Off patent, on the right track
When HerpDock highlighted doxorubicin, the crew took discover. Not simply because it labored within the simulation, however as a result of it was already accredited by the FDA.
‘We were excited when we realized that doxorubicin is already FDA-approved,’ stated Shukla. ‘That matters because its safety profile and dosing are already well understood. This drug could reach clinicians and patients much faster than a brand-new discovery.’
That is a much bigger deal than it would sound. Getting a brand new drug from a laboratory consequence to a pharmacist’s shelf usually takes over a decade and prices billions of {dollars}. An present accredited drug skips much of that queue.
Locking out unwelcome friends
Current herpes antivirals like acyclovir work by concentrating on the virus straight. This means they gum up the equipment the virus makes use of to repeat its DNA. That technique has labored properly for many years, nevertheless it means the medication are solely efficient so long as the virus doesn’t change sufficient to work round them and for folks with compromised immune techniques, a protracted and powerful course of acyclovir relations can take a toll.
Doxorubicin takes a special strategy. Rather than going after the virus itself, it blocks a signalling pathway inside human cells, a series of molecular switches known as PI3K-AKT-mTOR, that HSV-1 must get inside cells and begin replicating. Think of it like altering the locks on the door the virus makes use of to interrupt in, somewhat than making an attempt to cease the virus in transit.
Since this pathway is a part of the host cell somewhat than the virus, it’s a lot more durable for the virus to evolve round it. That is partly why the drug labored efficiently in opposition to acyclovir-resistant strains within the research; strains that present medication merely can not contact.
Evidential enquiries
While Herpdock recognized doxorubicin’s potential, Shukla’s crew nonetheless needed to verify that the drug actually might block herpes infections. These early phases of proof gathering occurred within the laboratory. This was not a scientific trial; no folks have been concerned.
The crew labored via three ranges of testing, every step extra advanced than the final.
First, they examined doxorubicin in human cells in a dish within the lab, together with corneal cells and most cancers cell strains. The drug constantly diminished the variety of virus particles that might replicate and did so at concentrations a lot decrease than these used for most cancers remedy. This issues as a result of the principle concern with doxorubicin is its toxicity at excessive doses.
Second, they used pig corneas, contaminated with HSV 1– a mannequin that carefully mimics human eye infections. The drug once more minimize viral ranges considerably, significantly when mixed with trifluridine, the usual eye drop antiviral.
Third, mice contaminated with HSV-1 within the eye have been handled topically with doxorubicin eye drops. Viral ranges within the eyes dropped, corneal harm was diminished, and crucially, there have been no indicators of drug-related toxicity to the guts, blood cells, or surrounding tissue, which is the usual fear with systemic doxorubicin.
The doses utilized in these eye-drop experiments have been roughly 3,000 occasions decrease than the focus of trifluridine utilized in commonplace remedy, and so they achieved comparable outcomes.
The acyclovir connection
One of the research’s extra sensible findings was what occurred when doxorubicin and present antivirals got collectively. The mixture produced outcomes properly past what both drug managed alone. In some cell-culture experiments, pairing the 2 diminished viral load by a whole bunch to hundreds of occasions greater than both drug by itself.
This issues as a result of acyclovir, taken long-term and on the doses generally required in immunocompromised sufferers, can harm the kidneys. If a small quantity of doxorubicin permits the identical viral suppression with a decrease acyclovir dose, that might cut back the danger for sufferers who want sustained remedy.
‘I enjoyed being a part of something that can really help people,’ stated Divya Kapoor, a graduate scholar researcher and co-author on the research. ‘This discovery has the potential to prevent herpes-related deaths and improve patient outcomes around the world, including for cancer patients who use doxorubicin.’
The ultimate stretch
The researchers are clear that extra work is required earlier than this turns into a remedy choice. The subsequent step can be human scientific trials, which take time to design, fund, and run. But as a result of doxorubicin is already accredited, the protection groundwork has largely been laid, which usually removes years from the method.
The folks more than likely to profit first are these whose immune techniques are already compromised. Chemotherapy sufferers specifically face a well-documented threat of herpes reactivation. The virus, which lies dormant in nerve tissue in most adults, can flare up when the immune system is suppressed. The researchers level out that some most cancers sufferers already receiving doxorubicin may be getting some inadvertent safety in opposition to this, a query value investigating.
For the final inhabitants with recurrent chilly sores or genital herpes, a topical doxorubicin product (an eye fixed drop or cream, for occasion) is a extra believable near-term utility. The drug wouldn’t have to flow into via the entire physique at cancer-chemotherapy ranges to be helpful.
An outdated most cancers drug, a brand new drug for Herpes
HSV-1 infects an estimated 4 billion folks worldwide, in line with the World Health Organization, making it some of the frequent viral infections in existence. It can be the main infectious reason for blindness globally. A brand new remedy choice, significantly one which works via a mechanism the virus can not simply evolve round, would fill a niche that has been open for a very long time.
References
Sharma P, et al. (2026). Host-directed novel mechanistic insights of doxorubicin reveal its efficacy in opposition to drug-resistant HSV-1 underscoring dangers with oncolytic virotherapy. Drug Resistance Updates, 86, 101362. https://doi.org/10.1016/j.drup.2026.101362
University of Illinois Chicago/EurekAlert press launch (March 24, 2026): ‘UIC research: A cancer drug that treats herpes, too.’ https://www.eurekalert.org/news-releases/1121079
World Health Organization (2023). Herpes simplex virus. https://www.who.int/news-room/fact-sheets/detail/herpes-simplex-virus
Sandherr M, et al. (2006). Antiviral prophylaxis in sufferers with haematological malignancies and strong tumours. Annals of Oncology, 17(7), 1051–1059. [Re: HSV reactivation risk during chemotherapy – cited in primary paper]
Kapoor D, Sharma P, Shukla D (2024). Emerging medication for the remedy of herpetic keratitis. Expert Opinion on Emerging Drugs, 29(2), 113–126. [HerpDock tool – cited in primary paper]
